IMA is loading

Main Financial Data 2013

Main Data: 31/12 Year 2013
Consolidated income statement (international practice in accordance with IAS/IFRS) Millions/Euro
– total revenues 760.93
– gross industrial income 314.16
– total operating cost 227.52
– operating profit 86.64
– net financial expenses 9.11
– group profit 51.54

 

Consolidated balance sheet Millions/Euro
– working capital 19.86
– non-current assets 248.64
– provision for severance indemnities and other provisions – 9.71
– net debt – 130.40
– equity pertaining to the group and minority interests 132.69

 

Other information Millions/Euro
– depreciation, amortization and impairment 27.16
– R & D costs 37.00

 

  Euro
Dividend per share 1.00
Extraordinary dividend per share 1.25

 

  No.
Employees 3,542

 

  Euro
Share capital 19,150,560

 

Main Data: 30/06 Year 2013
Consolidated income statement (international practice in accordance with IAS/IFRS) Millions/Euro
– total revenues 327.5
– gross industrial income 135.7
– total operating cost 102.0
– operating profit 33.7
– net financial expenses 3.7
– group profit (loss) 27.7

 

Consolidated balance sheet Millions/Euro
– working capital 50.5
– non-current assets 213.4
– provision for severance indemnities and other provisions 0.3
– net debt – 143.5
– equity pertaining to the group and minority interests 150.9

 

Other information Millions/Euro
– depreciation, amortization and impairment 8.4
– R & D costs 17.9

 

  No.
Employees 3,316

 

  Euro
Share capital  19,150,560

 

Net Sales by Sector: Year 2013
  Millions/Euro  
tea, food & other 267.40 35.1%
pharmaceutical 451.73 59.4%
ilapak 41.80 5.5%
Total 760.93 100.0%

 

Net Sales by Country: Year 2013
  Millions/Euro  
E.U. (excluding Italy) 254.68 33.5%
Other European countries 71.97 9.5%
North America 140.41 18.4%
Asia & Middle East 160.01 21.0%
Other countries 72.00 9.5%
Total exports 699.07 91.9%
Italy 61.86 8.1%
Total 760.93 100.0%
Dismissclose

IMA Pharma
@ Achema

Explore the dedicated website and get a free entry pass with IMA